Shijiazhuang Yiling Pharmaceutical (SHE:002603) will conduct clinical trials on the G201-Na capsule after obtaining approval from China's National Medical Products Administration, according to a Shenzhen bourse filing on Tuesday.
The drug will be tested for the prevention of premature ovulation in patients undergoing controlled ovarian hyperstimulation during assisted reproductive technology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments